Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Gastric Cancer

Free Subscription Articles published in Anticancer Res Retrieve available abstracts of 211 articles: HTML format

Single Articles

April 2021
1. JIN YZ, Gong YX, Liu Y, Xie DP, et al
   Peroxiredoxin V Silencing Elevates Susceptibility to Doxorubicin-induced Cell Apoptosis via ROS-dependent Mitochondrial Dysfunction in AGS Gastric Cancer Cells.
   Anticancer Res. 2021;41:1831-1840.
   PubMed     Abstract available
   
   
   March 2021
2. NAKANISHI Y, Hirota S, Hojo Y, Nakamura T, et al
   Pathological Complete Remission of Liver Metastases Correlates With Elimination of Tumor-infiltrating Tregs in Gastric Cancer.
   Anticancer Res. 2021;41:1571-1577.
   PubMed     Abstract available
   
   
   
3. ZHANG X, Yamamoto Y, Wang X, Sato M, et al
   MDM4 as a Prognostic Factor for Patients With Gastric Cancer With Low Expression of p53.
   Anticancer Res. 2021;41:1475-1483.
   PubMed     Abstract available
   
   
   February 2021
4. SHIMODA Y, Fujikawa H, Komori K, Watanabe H, et al
   Prognostic Factors for Gastric Cancer Patients With One Stage IV Factor who Underwent Conversion Surgery.
   Anticancer Res. 2021;41:1005-1012.
   PubMed     Abstract available
   
   
   
5. SUZUKI O, Yamaguchi T, Fukuchi M, Mochiki E, et al
   Prediction Model for Gastric Cancer With DNA Mismatch Repair Deficiency.
   Anticancer Res. 2021;41:975-982.
   PubMed     Abstract available
   
   
   
6. SASAHARA M, Kanda M, Shimizu D, Tanaka C, et al
   Tissue RNFT2 Expression Levels Are Associated With Peritoneal Recurrence and Poor Prognosis in Gastric Cancer.
   Anticancer Res. 2021;41:609-617.
   PubMed     Abstract available
   
   
   January 2021
7. KIM EJ, Kim M, Seo S, Kim MJ, et al
   Comparison of Sinusoidal Obstruction Syndrome in Gastric Cancer Patients Receiving S-1/oxaliplatin Versus Capecitabine/oxaliplatin.
   Anticancer Res. 2021;41:391-402.
   PubMed     Abstract available
   
   
   
8. LIM SC, Lee TB, Kang BS, Iy Han S, et al
   Extracellular Acidity-mediated Expression of cPLA2gamma Confers Resistance in Gastric Cancer Cells.
   Anticancer Res. 2021;41:211-218.
   PubMed     Abstract available
   
   
   
9. LEE GH, Park JW, Roh J, Kim YB, et al
   Association Between Waiting Time from Diagnosis to Endoscopic Submucosal Dissection and Non-curative Resection in Gastric Neoplasm.
   Anticancer Res. 2021;41:459-466.
   PubMed     Abstract available
   
   
   December 2020
10. FUJII H, Makiyama A, Iihara H, Okumura N, et al
    Cancer Cachexia Reduces the Efficacy of Nivolumab Treatment in Patients With Advanced Gastric Cancer.
    Anticancer Res. 2020;40:7067-7075.
    PubMed     Abstract available
    
    
    
11. NAKAMURA S, Kanda M, Shimizu D, Tanaka C, et al
    AMIGO2 Expression as a Potential Prognostic Biomarker for Gastric Cancer.
    Anticancer Res. 2020;40:6713-6721.
    PubMed     Abstract available
    
    
    November 2020
12. TRUMBULL D, Lemini R, Attwood K, Kukar M, et al
    Gastric Cancer Disparities Among Asian American Subpopulations.
    Anticancer Res. 2020;40:6381-6385.
    PubMed     Abstract available
    
    
    
13. CHEN YC, Wu CC, Tu YT, Chen YR, et al
    Involvement of the MicroRNA-1-LITAF Axis in Gastric Cancer Cell Growth and Invasion.
    Anticancer Res. 2020;40:6247-6256.
    PubMed     Abstract available
    
    
    
14. MAKI M, SOderstrOm D, Paloheimo L, Hendolin P, et al
    Helicobacter pylori (Hp) IgG ELISA of the New-Generation GastroPanel(R) Is Highly Accurate in Diagnosis of Hp-Infection in Gastroscopy Referral Patients.
    Anticancer Res. 2020;40:6387-6398.
    PubMed     Abstract available
    
    
    October 2020
15. HASHIMOTO I, Oue N, Kimura Y, Hiroshima Y, et al
    Clinical Significance of Glioma-associated Oncogene 1 Expression in Patients With Locally Advanced Gastric Cancer Administered Adjuvant Chemotherapy With S-1 After Curative Surgery.
    Anticancer Res. 2020;40:5815-5821.
    PubMed     Abstract available
    
    
    
16. ENDO S, Fujiwara Y, Yamatsuji T, Nishikawa K, et al
    Is it Necessary to Confirm Negative Margins in Gastrectomy for Peritoneal Lavage Cytology-positive Gastric Cancer?
    Anticancer Res. 2020;40:5807-5813.
    PubMed     Abstract available
    
    
    
17. UEJIMA C, Morimoto M, Yamamoto M, Hara K, et al
    Prognostic Significance of TYRO3 Receptor Tyrosine Kinase Expression in Gastric Cancer.
    Anticancer Res. 2020;40:5593-5600.
    PubMed     Abstract available
    
    
    
18. SUGISAWA N, Nishino H, Higuchi T, Park JH, et al
    A Gemcitabine Plus 5-Fluorouracil Combination Inhibits Gastric-Cancer Liver Metastasis in a PDOX Model: A Novel Treatment Strategy.
    Anticancer Res. 2020;40:5393-5397.
    PubMed     Abstract available
    
    
    August 2020
19. KIM EY, Jun KH, Yim K
    The Roles of Connexin 26, 32, and 43 as Prognostic Factors for Gastric Cancer.
    Anticancer Res. 2020;40:4537-4545.
    PubMed     Abstract available
    
    
    
20. KANAZAWA Y, Yamada T, Kakinuma D, Matsuno K, et al
    Skeletal Muscle Mass Depletion After Gastrectomy Negatively Affects the Prognosis of Patients With Gastric Cancer.
    Anticancer Res. 2020;40:4271-4279.
    PubMed     Abstract available
    
    
    July 2020
21. MAEZAWA Y, Aoyama T, Ju M, Komori K, et al
    The Impact of Severe Infectious Complications on Long-term Prognosis for Gastric Cancer.
    Anticancer Res. 2020;40:4067-4074.
    PubMed     Abstract available
    
    
    June 2020
22. KIM DS, Min K, Lee SK
    Cell Cycle Dysregulation Is Associated With 5-Fluorouracil Resistance in Gastric Cancer Cells.
    Anticancer Res. 2020;40:3247-3254.
    PubMed     Abstract available
    
    
    
23. YANG JW, Lee JH, Lee JS, Kim DC, et al
    Characteristics of Gastric Carcinomas With High ERCC1 Expression and the Prognostic Value of ERCC1 Expression.
    Anticancer Res. 2020;40:3203-3208.
    PubMed     Abstract available
    
    
    
24. KUBOTA T, Shoda K, Ogawa S, Matsumoto T, et al
    Oncological Safety of Ultrasonically Activated Surgical Devices During Gastric Cancer Surgery.
    Anticancer Res. 2020;40:3163-3167.
    PubMed     Abstract available
    
    
    
25. DI GIROLAMO M, Carbonetti F, Bonome P, Grossi A, et al
    Hydro-MDCT for Gastric Adenocarcinoma Staging. A Comparative Study With Surgical and Histopathological Findings for Selecting Patients for Echo-endoscopy.
    Anticancer Res. 2020;40:3401-3410.
    PubMed     Abstract available
    
    
    
26. TUNG KL, Wu YT, Liu C, Lin SC, et al
    EBV Rta-induced IL-6 Promotes Migration of Bystander Tumor Cells Through IL-6R/JAK/STAT3 Pathway In Vitro.
    Anticancer Res. 2020;40:3255-3264.
    PubMed     Abstract available
    
    
    May 2020
27. ILLUMINATI G, Pasqua R, Nardi P, Fratini C, et al
    Resection for Internal Jugular Vein Thrombosis and Cervical Lymph Nodes' Involvement from Gastric Cancer.
    Anticancer Res. 2020;40:2889-2893.
    PubMed     Abstract available
    
    
    April 2020
28. ENDO S, Ikenaga M, Yamada T, Tamura S, et al
    Prognostic Factors for Para-aortic Lymph Node Dissection After Neoadjuvant Chemotherapy for Gastric Cancer.
    Anticancer Res. 2020;40:2351-2357.
    PubMed     Abstract available
    
    
    
29. KATO K, Narita Y, Mitani S, Honda K, et al
    Efficacy of Cytotoxic Agents After Progression on Anti-PD-(L)1 Antibody for Pre-treated Metastatic Gastric Cancer.
    Anticancer Res. 2020;40:2247-2255.
    PubMed     Abstract available
    
    
    
30. BRAEUER F, Fischer I, Brammen L, Pressl G, et al
    Outcome in Patients Treated With Cytoreductive Surgery and HIPEC for Gastric Cancer With Peritoneal Carcinomatosis.
    Anticancer Res. 2020;40:2151-2156.
    PubMed     Abstract available
    
    
    
31. KIM HB, Lee HJ, Kim GB, Lim HJ, et al
    Clinical Significance of Jagged-1 Activated by APEX1 as a Chemoresistance Factor in Advanced Gastric Cancer.
    Anticancer Res. 2020;40:1897-1904.
    PubMed     Abstract available
    
    
    
32. SHIMODA Y, Yamada T, Komori K, Watanabe H, et al
    Effect of Muscle Mass Loss After Esophagectomy on Prognosis of Oesophageal Cancer.
    Anticancer Res. 2020;40:2275-2281.
    PubMed     Abstract available
    
    
    March 2020
33. VIRGILIO E, Proietti A, D'Urso R, Cardelli P, et al
    Elevated Gastric Juice Carbohydrate Antigen 72.4 (Ca 72.4) Is an Independent Prognostic Factor of Poor Survival for Gastric Cancer Patients.
    Anticancer Res. 2020;40:1691-1695.
    PubMed     Abstract available
    
    
    
34. WATANABE H, Hayashi T, Komori K, Hara K, et al
    Impact of Postoperative Complications on Recurrence in Patients With Stage II/III Gastric Cancer Who Received Adjuvant Chemotherapy With S-1.
    Anticancer Res. 2020;40:1683-1690.
    PubMed     Abstract available
    
    
    
35. HARA K, Aoyama T, Yamada T, Nakazono M, et al
    The Prognostic Value of the Perioperative Systemic Inflammation Score for Patients With Advanced Gastric Cancer.
    Anticancer Res. 2020;40:1503-1512.
    PubMed     Abstract available
    
    
    
36. MIGITA K, Matsumoto S, Wakatsuki K, Kunishige T, et al
    RNF126 as a Marker of Prognosis and Proliferation of Gastric Cancer.
    Anticancer Res. 2020;40:1367-1374.
    PubMed     Abstract available
    
    
    February 2020
37. SAWASAKI M, Tsubamoto H, Nakamoto Y, Kakuno A, et al
    S-1, Oxaliplatin, Nab-paclitaxel and Itraconazole for Conversion Surgery for Advanced or Recurrent Gastric Cancer.
    Anticancer Res. 2020;40:991-997.
    PubMed     Abstract available
    
    
    
38. LEMINI R, Jorgensen MS, Attwood K, Almerey T, et al
    Racial Disparities in Outcomes Among Asians With Gastric Cancer in the USA.
    Anticancer Res. 2020;40:881-889.
    PubMed     Abstract available
    
    
    
39. FU CK, Chien YC, Chuang HY, Wang YC, et al
    The Association of MMP7 Promoter Polymorphisms With Gastric Cancer.
    Anticancer Res. 2020;40:695-702.
    PubMed     Abstract available
    
    
    
40. AURELLO P, Cinquepalmi M, Petrucciani N, Moschetta G, et al
    Impact of Anastomotic Leakage on Overall and Disease-free Survival After Surgery for Gastric Carcinoma: A Systematic Review.
    Anticancer Res. 2020;40:619-624.
    PubMed     Abstract available
    
    
    
41. BAUMGARTNER R, Taghizadeh H, Jomrich G, Schoppmann SF, et al
    Utilization and Efficacy of Palliative Chemotherapy for Locally Advanced or Metastatic Gastroesophageal Carcinoma.
    Anticancer Res. 2020;40:965-975.
    PubMed     Abstract available
    
    
    January 2020
42. TAMAGAWA H, Aoyama T, Kano K, Numata M, et al
    The Impact of Intraoperative Blood Loss on the Long-term Prognosis after Curative Resection for Borrmann Type IV Gastric Cancer: A Retrospective Multicenter Study.
    Anticancer Res. 2020;40:405-412.
    PubMed     Abstract available
    
    
    
43. YOO HJ, Kim TJ, Kim DJ, Kim W, et al
    Role of COX2 as a Biomarker for Estimating Survival of Patients With Clinical Stage I Gastric Cancer.
    Anticancer Res. 2020;40:341-347.
    PubMed     Abstract available
    
    
    
44. ISHIKAWA D, Yoshikawa K, Takasu C, Kashihara H, et al
    Expression Level of MicroRNA-449a Predicts the Prognosis of Patients With Gastric Cancer.
    Anticancer Res. 2020;40:239-244.
    PubMed     Abstract available
    
    
    
45. TAKANO Y, Shida A, Fujisaki M, Mitsumori N, et al
    Prognostic Significance of ZKSCAN3 (ZNF306) Expression in Gastric Carcinoma.
    Anticancer Res. 2020;40:81-86.
    PubMed     Abstract available
    
    
    
46. KIJIMA T, Arigami T, Uenosono Y, Hiraki T, et al
    Comparison of HER2 Status Before and After Trastuzumab-based Chemotherapy in Patients With Advanced Gastric Cancer.
    Anticancer Res. 2020;40:75-80.
    PubMed     Abstract available
    
    
    December 2019
47. BAEK JH, Park DJ, Kim GY, Cheon J, et al
    Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer.
    Anticancer Res. 2019;39:6973-6979.
    PubMed     Abstract available
    
    
    
48. KOSUGA T, Konishi T, Kubota T, Shoda K, et al
    Value of Prognostic Nutritional Index as a Predictor of Lymph Node Metastasis in Gastric Cancer.
    Anticancer Res. 2019;39:6843-6849.
    PubMed     Abstract available
    
    
    
49. YAMAMOTO Y, Kuroda K, Sera T, Sugimoto A, et al
    The Clinicopathological Significance of the CXCR2 Ligands, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8 in Gastric Cancer.
    Anticancer Res. 2019;39:6645-6652.
    PubMed     Abstract available
    
    
    
50. ONEYAMA M, Sakamoto N, Oue N, Kimura Y, et al
    Clinical Significance of KIAA1199 as a Novel Target for Gastric Cancer Drug Therapy.
    Anticancer Res. 2019;39:6567-6573.
    PubMed     Abstract available
    
    
    
51. KIM JS, Bae GE, Kim KH, Lee SI, et al
    Prognostic Significance of LC3B and p62/SQSTM1 Expression in Gastric Adenocarcinoma.
    Anticancer Res. 2019;39:6711-6722.
    PubMed     Abstract available
    
    
    November 2019
52. NAEEM B, Ayub A
    Primary Pediatric Non-Hodgkin Lymphomas of the Gastrointestinal Tract: A Population-based Analysis.
    Anticancer Res. 2019;39:6413-6416.
    PubMed     Abstract available
    
    
    
53. TAKAHASHI Y, Fukuyama T, Futawatari N, Ichiki Y, et al
    Expression of Kita-Kyushu Lung Cancer Antigen-1 as Detected by a Novel Monoclonal Antibody in Gastric Cancer.
    Anticancer Res. 2019;39:6259-6263.
    PubMed     Abstract available
    
    
    
54. ENDO S, Nishikawa K, Fujitani K, Matsuyama J, et al
    Is D2 Lymphadenectomy Essential for Cytology-positive Gastric Cancer? A Retrospective Analysis.
    Anticancer Res. 2019;39:6209-6216.
    PubMed     Abstract available
    
    
    
55. SAWAKI K, Kanda M, Umeda S, Miwa T, et al
    Level of Melanotransferrin in Tissue and Sera Serves as a Prognostic Marker of Gastric Cancer.
    Anticancer Res. 2019;39:6125-6133.
    PubMed     Abstract available
    
    
    
56. NAKATA S, Fujita M, Nakanishi H
    Efficacy of Afatinib and Lapatinib Against HER2 Gene-amplified Trastuzumab-sensitive and -resistant Human Gastric Cancer Cells.
    Anticancer Res. 2019;39:5927-5932.
    PubMed     Abstract available
    
    
    
57. ENDO M, Kanda M, Sawaki K, Shimizu D, et al
    Tissue Expression of Melanoma-associated Antigen A6 and Clinical Characteristics of Gastric Cancer.
    Anticancer Res. 2019;39:5903-5910.
    PubMed     Abstract available
    
    
    
58. KHING TM, Po WW, Sohn UD
    Fluoxetine Enhances Anti-tumor Activity of Paclitaxel in Gastric Adenocarcinoma Cells by Triggering Apoptosis and Necroptosis.
    Anticancer Res. 2019;39:6155-6163.
    PubMed     Abstract available
    
    
    October 2019
59. YU JI, Lim DH, Lee J, Kang WK, et al
    Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (</=45 Years) With Gastric Cancer.
    Anticancer Res. 2019;39:5811-5820.
    PubMed     Abstract available
    
    
    
60. HASHIMOTO I, Sakamaki K, Oue N, Kimura Y, et al
    Clinical Significance of PRKCI Gene Expression in Cancerous Tissue in Patients With Gastric Cancer.
    Anticancer Res. 2019;39:5715-5720.
    PubMed     Abstract available
    
    
    
61. TSAI KW, Tsai CY, Chou NH, Wang KC, et al
    Aberrant DNA Hypermethylation Silenced LncRNA Expression in Gastric Cancer.
    Anticancer Res. 2019;39:5381-5391.
    PubMed     Abstract available
    
    
    September 2019
62. ANDO K, Hamada K, Watanabe M, Ohkuma R, et al
    Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors.
    Anticancer Res. 2019;39:5195-5201.
    PubMed     Abstract available
    
    
    
63. NISHIMURA S, Yashiro M, Sera T, Yamamoto Y, et al
    Feasibility of Identifying Patients at High Risk of Hereditary Gastric Cancer Based on Clinicopathological Variables.
    Anticancer Res. 2019;39:5057-5064.
    PubMed     Abstract available
    
    
    
64. KUBOTA T, Ichikawa D, Kosuga T, Shoda K, et al
    Does Robotic Distal Gastrectomy Facilitate Minimally Invasive Surgery for Gastric Cancer?
    Anticancer Res. 2019;39:5033-5038.
    PubMed     Abstract available
    
    
    
65. ITO A, Nakanishi H, Yoshimura M, Ito S, et al
    Dynamics of Circulating Tumor Cells Early After Targeting Therapy to Human EGFR-mutated Lung Cancers and HER2 Gene-amplified Gastric Cancers in Mice.
    Anticancer Res. 2019;39:4711-4720.
    PubMed     Abstract available
    
    
    
66. WOLL E, Eisterer W, Gerger A, Kuhr T, et al
    Treatment Algorithm for Patients With Gastric Adenocarcinoma: An Austrian Consensus on Systemic Therapy.
    Anticancer Res. 2019;39:4589-4596.
    PubMed     Abstract available
    
    
    August 2019
67. YAMAMOTO K, Hirao M, Nishikawa K, Omori T, et al
    Sarcopenia Is Associated With Impaired Overall Survival After Gastrectomy for Elderly Gastric Cancer.
    Anticancer Res. 2019;39:4297-4303.
    PubMed     Abstract available
    
    
    
68. NAKAZAWA N, Ogata K, Yokobori T, Ide M, et al
    Low IRBIT Levels Are Associated With Chemo-resistance in Gastric Cancer Patients.
    Anticancer Res. 2019;39:4111-4116.
    PubMed     Abstract available
    
    
    
69. VIRGILIO E, Giarnieri E, Montagnini M, Villani S, et al
    Advances in Intraluminal Exfoliative Cytology of Gastric Cancer: Oncologic Implication of the Sixth Metastatic Route (Metastasis VI).
    Anticancer Res. 2019;39:4019-4022.
    PubMed     Abstract available
    
    
    
70. KANG BW, Baek DW, Kang H, Baek JH, et al
    Novel Therapeutic Approaches for Epstein-Barr Virus Associated Gastric Cancer.
    Anticancer Res. 2019;39:4003-4010.
    PubMed     Abstract available
    
    
    June 2019
71. HIRAHARA N, Tajima Y, Fujii Y, Kaji S, et al
    Comprehensive Analysis of Red Blood Cell Distribution Width as a Preoperative Prognostic Predictor in Gastric Cancer.
    Anticancer Res. 2019;39:3121-3130.
    PubMed     Abstract available
    
    
    
72. SATO Y, Inokuchi M, Takagi Y, Kojima K, et al
    IGFBP1 Is a Predictive Factor for Haematogenous Metastasis in Patients With Gastric Cancer.
    Anticancer Res. 2019;39:2829-2837.
    PubMed     Abstract available
    
    
    
73. TAKI T, Hoya Y, Nakada K, Kawamura M, et al
    Gastric Emptying Improved Significantly After PRG Compared to Billroth-I Reconstruction: Assessment of Gastric Emptying With a (13)C-Breath Test.
    Anticancer Res. 2019;39:3227-3230.
    PubMed     Abstract available
    
    
    May 2019
74. MURAKAMI Y, Saito H, Shimizu S, Kono Y, et al
    Neutrophil-to-Lymphocyte Ratio as a Prognostic Indicator in Patients With Unresectable Gastric Cancer.
    Anticancer Res. 2019;39:2583-2589.
    PubMed     Abstract available
    
    
    
75. MATSUBARA D, Konishi H, Kubota T, Kosuga T, et al
    Comparison of Clinical Outcomes of Gastrojejunal Bypass and Gastrectomy in Patients With Metastatic Gastric Cancer.
    Anticancer Res. 2019;39:2545-2551.
    PubMed     Abstract available
    
    
    
76. KUWADA K, Kuroda S, Kikuchi S, Yoshida R, et al
    Clinical Impact of Sarcopenia on Gastric Cancer.
    Anticancer Res. 2019;39:2241-2249.
    PubMed     Abstract available
    
    
    April 2019
77. YOSHIDA Y, Beppu T, Kinoshita K, Sato N, et al
    Five-year Recurrence-free Survival After Surgery Followed by Oral Chemotherapy for Gastric Cancer With Portal Vein Tumor Thrombosis.
    Anticancer Res. 2019;39:2233-2238.
    PubMed     Abstract available
    
    
    
78. SEO AN, Kang BW, Bae HI, Kwon OK, et al
    Exon 9 Mutation of PIK3CA Associated With Poor Survival in Patients With Epstein-Barr Virus-associated Gastric Cancer.
    Anticancer Res. 2019;39:2145-2154.
    PubMed     Abstract available
    
    
    
79. LIU JB, Jian T, Yue C, Chen D, et al
    Chemo-resistant Gastric Cancer Associated Gene Expression Signature: Bioinformatics Analysis Based on Gene Expression Omnibus.
    Anticancer Res. 2019;39:1689-1698.
    PubMed     Abstract available
    
    
    
80. AURELLO P, Berardi G, Moschetta G, Cinquepalmi M, et al
    Recurrence Following Anastomotic Leakage After Surgery for Carcinoma of the Distal Esophagus and Gastroesophageal Junction: A Systematic Review.
    Anticancer Res. 2019;39:1651-1660.
    PubMed     Abstract available
    
    
    March 2019
81. SAITO R, Kawaguchi Y, Akaike H, Shiraishi K, et al
    Prognostic Significance of Lymph Node Dissection Along the Upper-third-stomach in Patients With Lower-third Gastric Cancer.
    Anticancer Res. 2019;39:1485-1489.
    PubMed     Abstract available
    
    
    
82. NAKAJI YU, Saeki H, Kudou K, Nakanishi R, et al
    Short- and Long-term Outcomes of Surgical Treatment for Remnant Gastric Cancer After Distal Gastrectomy.
    Anticancer Res. 2019;39:1411-1415.
    PubMed     Abstract available
    
    
    February 2019
83. AOYAMA T, Yoshikawa T, Maezawa Y, Segami K, et al
    Influence of Postoperative Surgical Complications After Gastrectomy on Body Weight and Body Composition Changes in Patients With Gastric Cancer.
    Anticancer Res. 2019;39:1073-1078.
    PubMed     Abstract available
    
    
    
84. ENDO S, Kurokawa Y, Gamoh M, Kimura Y, et al
    Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202.
    Anticancer Res. 2019;39:1059-1065.
    PubMed     Abstract available
    
    
    
85. VIRGILIO E, Giarnieri E, Giovagnoli MR, Montagnini M, et al
    Gastric Lavage Malignant Cells (yGL) and Hypohemoglobinemia (yAnemia) as New Systems of Tumor Regression Grading and Prognostic Prediction for Gastric Cancer After Neoadjuvant Treatment.
    Anticancer Res. 2019;39:1019-1027.
    PubMed     Abstract available
    
    
    
86. TAMURA T, Sakurai K, Nambara M, Miki Y, et al
    Adverse Effects of Preoperative Sarcopenia on Postoperative Complications of Patients With Gastric Cancer.
    Anticancer Res. 2019;39:987-992.
    PubMed     Abstract available
    
    
    
87. ELTWERI AM, Thomas AL, Chung WY, Morgan B, et al
    The Effect of Supplementary Omegaven(R) on the Clinical Outcome of Patients With Advanced Esophagogastric Adenocarcinoma Receiving Palliative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy: A Phase II clinical trial.
    Anticancer Res. 2019;39:853-861.
    PubMed     Abstract available
    
    
    January 2019
88. SAITO H, Shimizu S, Kono Y, Murakami Y, et al
    PD-1 Expression on Circulating CD8(+) T-Cells as a Prognostic Marker for Patients With Gastric Cancer.
    Anticancer Res. 2019;39:443-448.
    PubMed     Abstract available
    
    
    
89. NUMAKURA S, Uozaki H, Kikuchi Y, Watabe S, et al
    Mesenchymal Stem Cell Marker Expression in Gastric Cancer Stroma.
    Anticancer Res. 2019;39:387-393.
    PubMed     Abstract available
    
    
    
90. BAE GE, Kim HS, Won KY, Kim GY, et al
    Lower Sympathetic Nervous System Density and beta-adrenoreceptor Expression Are Involved in Gastric Cancer Progression.
    Anticancer Res. 2019;39:231-236.
    PubMed     Abstract available
    
    
    
91. KIM DJ, Kim W
    Lower Esophageal Sphincter-preserving Anastomosis Is an Acceptable Reconstruction Method Following Laparoscopy-assisted Proximal Gastrectomy.
    Anticancer Res. 2019;39:425-430.
    PubMed     Abstract available
    
    
    December 2018
92. SATO S, Kunisaki C, Tanaka Y, Sato K, et al
    A Phase II Study of Tri-weekly Low-dose Nab-paclitaxel Chemotherapy for Patients with Advanced Gastric Cancer.
    Anticancer Res. 2018;38:6911-6917.
    PubMed     Abstract available
    
    
    
93. MOCHIZUKI K, Kawai M, Odate T, Tahara I, et al
    SMARCB1/INI1 Is Diagnostically Useful in Distinguishing alpha-Fetoprotein-producing Gastric Carcinoma from Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:6865-6868.
    PubMed     Abstract available
    
    
    
94. GIATROMANOLAKI A, Koukourakis MI, Georgiou I, Kouroupi M, et al
    LC3A, LC3B and Beclin-1 Expression in Gastric Cancer.
    Anticancer Res. 2018;38:6827-6833.
    PubMed     Abstract available
    
    
    
95. YANG W, Cai J, Zhang H, Wang G, et al
    Effects of Lidocaine and Ropivacaine on Gastric Cancer Cells Through Down-regulation of ERK1/2 Phosphorylation In Vitro.
    Anticancer Res. 2018;38:6729-6735.
    PubMed     Abstract available
    
    
    
96. LARBRE V, Alyami M, Mercier F, Vantard N, et al
    No Renal Toxicity After Repeated Treatment with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Unresectable Peritoneal Metastasis.
    Anticancer Res. 2018;38:6869-6875.
    PubMed     Abstract available
    
    
    November 2018
97. LUCCHETTI J, Formica V, Giuliano G, Coletta D, et al
    Case Report of a Patient with Breast Metastasis from Gastric Cancer Treated with Paclitaxel and Ramucirumab Plus Regional Hyperthermia.
    Anticancer Res. 2018;38:6561-6564.
    PubMed     Abstract available
    
    
    
98. FUKUCHI M, Mochiki E, Ishiguro T, Kumagai Y, et al
    Prognostic Significance of Conversion Surgery Following First- or Second-line Chemotherapy for Unresectable Gastric Cancer.
    Anticancer Res. 2018;38:6473-6478.
    PubMed     Abstract available
    
    
    
99. DE FATIMA FERREIRA BORGES DA C, DE Castro Sant' Anna C, Muniz JAPC, DA Rocha CAM, et al
    Deregulation of the SRC Family Tyrosine Kinases in Gastric Carcinogenesis in Non-human Primates.
    Anticancer Res. 2018;38:6317-6320.
    PubMed     Abstract available
    
    
    
100. SEKINO N, Kano M, Matsumoto Y, Sakata H, et al
     The Antitumor Effects of Metformin on Gastric Cancer In Vitro and on Peritoneal Metastasis.
     Anticancer Res. 2018;38:6263-6269.
     PubMed     Abstract available
     
     
     
101. KIM HM, Jeong I, Kim HJ, Kang SK, et al
     Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer.
     Anticancer Res. 2018;38:6171-6180.
     PubMed     Abstract available
     
     
     
102. MIYOSHI S, Tsugawa H, Matsuzaki J, Hirata K, et al
     Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression.
     Anticancer Res. 2018;38:6163-6170.
     PubMed     Abstract available
     
     
     
103. UETA K, Otowa Y, Kakeji Y, Hirashima M, et al
     PROX1 Is Associated with Cancer Progression and Prognosis in Gastric Cancer.
     Anticancer Res. 2018;38:6139-6145.
     PubMed     Abstract available
     
     
     
104. KAWAKUBO E, Matsumoto T, Yoshiya K, Yamashita S, et al
     BUBR1 Insufficiency Is Correlated with eNOS Reduction Experimentally In Vitro and In Vivo, and in Gastric Cancer Tissue.
     Anticancer Res. 2018;38:6099-6106.
     PubMed     Abstract available
     
     
     October 2018
105. TANAKA Y, Kunisaki C, Izumisawa Y, Makino H, et al
     A Phase I/II Study of NAC with Docetaxel, Cisplatin, and S-1 for Stage III Gastric Cancer.
     Anticancer Res. 2018;38:6015-6021.
     PubMed     Abstract available
     
     
     
106. SHINKAI M, Imano M, Chiba Y, Hiraki Y, et al
     Intraperitoneal and Systemic Chemotherapy for Patients with Gastric Cancer with Peritoneal Metastasis: A Phase II Trial.
     Anticancer Res. 2018;38:5975-5981.
     PubMed     Abstract available
     
     
     
107. SHINKAI M, Imano M, Chiba Y, Hiraki Y, et al
     Intraperitoneal Administration of Paclitaxel Followed by Paclitaxel, Cisplatin, and S-1 Chemotherapy for Cytology-positive Gastric Cancer: A Feasibility Study.
     Anticancer Res. 2018;38:5969-5974.
     PubMed     Abstract available
     
     
     
108. SUGIYAMA K, Narita Y, Mitani S, Honda K, et al
     Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer.
     Anticancer Res. 2018;38:5859-5866.
     PubMed     Abstract available
     
     
     
109. GONZALEZ-HORMAZABAL P, Romero S, Musleh M, Bustamante M, et al
     IL-8-251T>A (rs4073) Polymorphism Is Associated with Prognosis in Gastric Cancer Patients.
     Anticancer Res. 2018;38:5703-5708.
     PubMed     Abstract available
     
     
     
110. VIRGILIO E, Ceci D, Cavallini M
     Surgical Endoscopic Vacuum-assisted Closure Therapy (EVAC) in Treating Anastomotic Leakages After Major Resective Surgery of Esophageal and Gastric Cancer.
     Anticancer Res. 2018;38:5581-5587.
     PubMed     Abstract available
     
     
     
111. ATHAUDA A, Watkins D, Mohammed K, Chau I, et al
     Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre.
     Anticancer Res. 2018;38:5943-5949.
     PubMed     Abstract available
     
     
     
112. ISHIGAMI S, Aridome K, Arigami T, Uenosono Y, et al
     Roux-en-Y Plus Distal Jejunal Pouch After Total Gastrectomy: A Prospective Study.
     Anticancer Res. 2018;38:5837-5841.
     PubMed     Abstract available
     
     
     
113. PARK R, Williamson S, Kasi A, Saeed A, et al
     Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer.
     Anticancer Res. 2018;38:5569-5580.
     PubMed     Abstract available
     
     
     September 2018
114. KOMATSU S, Kosuga T, Kubota T, Okamoto K, et al
     Preoperative Low Weight Affects Long-term Outcomes Following Curative Gastrectomy for Gastric Cancer.
     Anticancer Res. 2018;38:5331-5337.
     PubMed     Abstract available
     
     
     
115. ISHIDA R, Kanaji S, Maehara R, Hasegawa H, et al
     Significance of Additional Gastrectomy Including Endoscopic Submucosal Dissection Scar for Gastric Cancer.
     Anticancer Res. 2018;38:5289-5294.
     PubMed     Abstract available
     
     
     August 2018
116. HIRAHARA N, Tajima Y, Fujii Y, Yamamoto T, et al
     Preoperative Prognostic Nutritional Index Predicts Long-term Outcome in Gastric Cancer: A Propensity Score-matched Analysis.
     Anticancer Res. 2018;38:4735-4746.
     PubMed     Abstract available
     
     
     
117. HOWARD R, Al Diffalha S, Pimiento J, Mejia J, et al
     CD133 Expression as a Helicobacter pylori-independent Biomarker of Gastric Cancer Progression.
     Anticancer Res. 2018;38:4443-4448.
     PubMed     Abstract available
     
     
     
118. KASHIHARA H, Shimada M, Yoshikawa K, Higashijima J, et al
     The Effect of Roux-en-Y Reconstruction on Type 2 Diabetes in the Early Postoperative Period.
     Anticancer Res. 2018;38:4901-4905.
     PubMed     Abstract available
     
     
     July 2018
119. ROMERO S, Musleh M, Bustamante M, Stambuk J, et al
     Polymorphisms in TWIST1 and ZEB1 Are Associated with Prognosis of Gastric Cancer Patients.
     Anticancer Res. 2018;38:3871-3877.
     PubMed     Abstract available
     
     
     June 2018
120. TANAKA H, Tamura T, Toyokawa T, Muguruma K, et al
     Clinical Relevance of Postoperative Neutrophil-Lymphocyte Ratio (NLR) to Recurrence After Adjuvant Chemotherapy of S-1 for Gastric Cancer.
     Anticancer Res. 2018;38:3745-3751.
     PubMed     Abstract available
     
     
     
121. OBERMANNOVA R, Redova-Lojova M, Vychytilova-Faltejskova P, Grell P, et al
     Tumor Expression of miR-10b, miR-21, miR-143 and miR-145 Is Related to Clinicopathological Features of Gastric Cancer in a Central European Population.
     Anticancer Res. 2018;38:3719-3724.
     PubMed     Abstract available
     
     
     
122. MARANO L, Rondelli F, Bartoli A, Testini M, et al
     Oncologic Effectiveness and Safety of Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma: Meta-analysis of Randomized Controlled Trials.
     Anticancer Res. 2018;38:3609-3617.
     PubMed     Abstract available
     
     
     
123. NISHI M, Yoshikawa K, Higashijima J, Tokunaga T, et al
     The Impact of Indoleamine 2,3-dioxygenase (IDO) Expression on Stage III Gastric Cancer.
     Anticancer Res. 2018;38:3387-3392.
     PubMed     Abstract available
     
     
     
124. CHOU NH, Lo YH, Wang KC, Kang CH, et al
     MiR-193a-5p and -3p Play a Distinct Role in Gastric Cancer: miR-193a-3p Suppresses Gastric Cancer Cell Growth by Targeting ETS1 and CCND1.
     Anticancer Res. 2018;38:3309-3318.
     PubMed     Abstract available
     
     
     
125. BOLM L, Kasmann L, Paysen A, Karapetis C, et al
     Multimodal Anti-tumor Approaches Combined with Immunotherapy to Overcome Tumor Resistance in Esophageal and Gastric Cancer.
     Anticancer Res. 2018;38:3231-3242.
     PubMed     Abstract available
     
     
     
126. CHUNG T, DO SI, Na K, Kim G, et al
     Stromal p16 Overexpression in Gastric-type Mucinous Carcinoma of the Uterine Cervix.
     Anticancer Res. 2018;38:3551-3558.
     PubMed     Abstract available
     
     
     May 2018
127. HWANG GY, Baek DW, Cho HJ, Lee SJ, et al
     Elevated Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients with Advanced Gastric Cancer Treated with Trastuzumab Combination Chemotherapy.
     Anticancer Res. 2018;38:3151-3156.
     PubMed     Abstract available
     
     
     
128. KIUCHI J, Komatsu S, Kosuga T, Kubota T, et al
     Long-term Postoperative Nutritional Status Affects Prognosis Even After Infectious Complications in Gastric Cancer.
     Anticancer Res. 2018;38:3133-3138.
     PubMed     Abstract available
     
     
     
129. IWABU J, Namikawa T, Tsuda S, Kitagawa H, et al
     Successful Distal Gastrectomy for Gastric Cancer with Child-Pugh Class B Alcoholic Liver Cirrhosis.
     Anticancer Res. 2018;38:3085-3087.
     PubMed     Abstract available
     
     
     
130. MARUYAMA S, Furuya S, Shiraishi K, Shimizu H, et al
     Podoplanin Expression as a Prognostic Factor in Gastric Cancer.
     Anticancer Res. 2018;38:2717-2722.
     PubMed     Abstract available
     
     
     
131. MONDLANE G, Ureba A, Gubanski M, Lind PA, et al
     Estimation of Risk of Normal-tissue Toxicity Following Gastric Cancer Radiotherapy with Photon- or Scanned Proton-beams.
     Anticancer Res. 2018;38:2619-2625.
     PubMed     Abstract available
     
     
     April 2018
132. OTOWA Y, Suzuki S, Kanaji S, Harada H, et al
     Curative Gastrectomy with Perioperative Chemotherapy Improves the Survival for Unresectable Gastric Cancer.
     Anticancer Res. 2018;38:2363-2368.
     PubMed     Abstract available
     
     
     
133. HARUTA Y, Nakanishi R, Jogo T, Nakashima Y, et al
     Gastric Cancer of "Crawling Type" Detected by Additional Gastrectomy After Endoscopic Submucosal Resection.
     Anticancer Res. 2018;38:2335-2338.
     PubMed     Abstract available
     
     
     
134. VIRGILIO E, Balducci G, Mercantini P, Giarnieri E, et al
     Laparoscopic Intragastric Surgery for Treating Early Gastric Cancer.
     Anticancer Res. 2018;38:1911-1916.
     PubMed     Abstract available
     
     
     
135. CHIU YM, Tsai CL, Kao JT, Hsieh CT, et al
     PD-1 and PD-L1 Up-regulation Promotes T-cell Apoptosis in Gastric Adenocarcinoma.
     Anticancer Res. 2018;38:2069-2078.
     PubMed     Abstract available
     
     
     
136. TSAI CL, Chiu YM, Ho TY, Hsieh CT, et al
     Gallic Acid Induces Apoptosis in Human Gastric Adenocarcinoma Cells.
     Anticancer Res. 2018;38:2057-2067.
     PubMed     Abstract available
     
     
     March 2018
137. ARATANI K, Sakuramoto S, Chuman M, Kasuya M, et al
     Laparoscopy-assisted Distal Gastrectomy for Gastric Cancer in Elderly Patients: Surgical Outcomes and Prognosis.
     Anticancer Res. 2018;38:1721-1725.
     PubMed     Abstract available
     
     
     
138. INOKUCHI M, Nakagawa M, Baogok N, Takagi Y, et al
     Prognostic Significance of High EphA1-4 Expression Levels in Locally Advanced Gastric Cancer.
     Anticancer Res. 2018;38:1685-1693.
     PubMed     Abstract available
     
     
     
139. IGUCHI K, Kunisaki C, Sato S, Tanaka Y, et al
     Evaluation of Optimal Lymph Node Dissection in Remnant Gastric Cancer Based on Initial Distal Gastrectomy.
     Anticancer Res. 2018;38:1677-1683.
     PubMed     Abstract available
     
     
     
140. KINOSHITA K, Beppu T, Miyata T, Kuramoto K, et al
     A Case of 15-Year Recurrence-free Survival After Microwave Coagulation Therapy for Liver Metastasis from Gastric Cancer.
     Anticancer Res. 2018;38:1595-1598.
     PubMed     Abstract available
     
     
     
141. HONMA R, Sakamoto N, Ishikawa A, Taniyama D, et al
     Clinicopathological and Prognostic Significance of Epithelial Gremlin1 Expression in Gastric Cancer.
     Anticancer Res. 2018;38:1419-1425.
     PubMed     Abstract available
     
     
     
142. VIRGILIO E, Giarnieri E, Giovagnoli MR, Montagnini M, et al
     Gastric Cancer Cells in Peritoneal Lavage Fluid: A Systematic Review Comparing Cytological with Molecular Detection for Diagnosis of Peritoneal Metastases and Prediction of Peritoneal Recurrences.
     Anticancer Res. 2018;38:1255-1262.
     PubMed     Abstract available
     
     
     February 2018
143. PALAJ J, Keckes S, Marek V, Dyttert D, et al
     Fibrinogen Levels Are Associated with Lymph Node Involvement and Overall Survival in Gastric Cancer Patients.
     Anticancer Res. 2018;38:1097-1104.
     PubMed     Abstract available
     
     
     
144. NAKAMURA A, Matsunaga W, Gotoh A
     Autophagy Induced by Naftopidil Inhibits Apoptosis of Human Gastric Cancer Cells.
     Anticancer Res. 2018;38:803-809.
     PubMed     Abstract available
     
     
     
145. VIRGILIO E, Giarnieri E, Giovagnoli MR, Montagnini M, et al
     Gastric Juice MicroRNAs as Potential Biomarkers for Screening Gastric Cancer: A Systematic Review.
     Anticancer Res. 2018;38:613-616.
     PubMed     Abstract available
     
     
     
146. CEAUSU AR, Ciolofan A, Cimpean AM, Magheti A, et al
     The Mesenchymal-Epithelial and Epithelial-Mesenchymal Cellular Plasticity of Liver Metastases with Digestive Origin.
     Anticancer Res. 2018;38:811-816.
     PubMed     Abstract available
     
     
     January 2018
147. VIRGILIO E, Balducci G, Mercantini P, Giarnieri E, et al
     Utility of Nasogastric Tube for Medical and Surgical Oncology of Gastric Cancer: A Prospective Institutional Study on a New and Precious Application of an Old and Economic Device.
     Anticancer Res. 2018;38:433-439.
     PubMed     Abstract available
     
     
     
148. SHIN SH, Park SS, Ju EJ, Park J, et al
     Establishment of a Patient-derived Xenograft for Development of Personalized HER2-targeting Therapy in Gastric Cancer.
     Anticancer Res. 2018;38:287-293.
     PubMed     Abstract available
     
     
     
149. SAITO H, Kono Y, Murakami Y, Shishido Y, et al
     Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression.
     Anticancer Res. 2018;38:107-112.
     PubMed     Abstract available
     
     
     
150. DOMINGUEZ C, Rosa M, George TB, Pimiento J, et al
     Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH.
     Anticancer Res. 2018;38:367-372.
     PubMed     Abstract available
     
     
     December 2017
151. MASUISHI T, Kadowaki S, Kondo M, Komori A, et al
     FOLFOX as First-line Therapy for Gastric Cancer with Severe Peritoneal Metastasis.
     Anticancer Res. 2017;37:7037-7042.
     PubMed     Abstract available
     
     
     
152. FUJII H, Iihara H, Kajikawa N, Kobayashi R, et al
     Control of Nausea Based on Risk Analysis in Patients with Esophageal and Gastric Cancer Who Received Cisplatin-based Chemotherapy.
     Anticancer Res. 2017;37:6831-6837.
     PubMed     Abstract available
     
     
     
153. INOKUCHI M, Higuchi K, Takagi Y, Tanioka T, et al
     Cadherin 5 Is a Significant Risk Factor for Hematogenous Recurrence and a Prognostic Factor in Locally Advanced Gastric Cancer.
     Anticancer Res. 2017;37:6807-6813.
     PubMed     Abstract available
     
     
     
154. NISHI M, Batsaikhan BE, Yoshikawa K, Higashijima J, et al
     High STAT4 Expression Indicates Better Disease-free Survival in Patients with Gastric Cancer.
     Anticancer Res. 2017;37:6723-6729.
     PubMed     Abstract available
     
     
     
155. ANDREOU A, Pesthy S, Struecker B, Dadras M, et al
     Incidence and Risk Factors of Symptomatic Hiatal Hernia Following Resection for Gastric and Esophageal Cancer.
     Anticancer Res. 2017;37:7031-7036.
     PubMed     Abstract available
     
     
     November 2017
156. KANAZAWA Y, Yamada T, Fujita I, Kakinuma D, et al
     In Vitro Chemosensitivity Test for Gastric Cancer Specimens Predicts Effectiveness of Oxaliplatin and 5-Fluorouracil.
     Anticancer Res. 2017;37:6401-6405.
     PubMed     Abstract available
     
     
     October 2017
157. VIRGILIO E, Balducci G, Mercantini P, Ferri M, et al
     Reconstruction After Distal Gastrectomy for Gastric Cancer: Billroth 2 or Roux-En-Y Procedure?
     Anticancer Res. 2017;37:5595-5602.
     PubMed     Abstract available
     
     
     
158. WOLL E, Thaler J, Keil F, Gruenberger B, et al
     Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3.
     Anticancer Res. 2017;37:5553-5558.
     PubMed     Abstract available
     
     
     
159. LEE AA, Poddar N, Hammami MB, Veerapong J, et al
     Gastric Spindle Cell Neuroendocrine Tumor Mimicking Gastrointestinal Stromal Tumor: Unique Morphology and Diagnostic Pitfall.
     Anticancer Res. 2017;37:5893-5897.
     PubMed     Abstract available
     
     
     September 2017
160. PACHNIA D, Drop B, Dworzanska A, Kliszczewska E, et al
     Transforming Growth Factor-beta, Interleukin-10, and Serological Markers in EBV-associated Gastric Carcinoma.
     Anticancer Res. 2017;37:4853-4858.
     PubMed     Abstract available
     
     
     August 2017
161. YIN J, Song JN, Bai ZG, Cai J, et al
     Gastric Cancer Mortality Trends in China (2006-2013) Reveal Increasing Mortality in Young Subjects.
     Anticancer Res. 2017;37:4671-4679.
     PubMed     Abstract available
     
     
     
162. DONG W, Li B, Wang J, Song Y, et al
     Exploration of the Radiotherapeutic Clinical Target Volume Delineation for Gastric Cancer from Lymph Node Metastases.
     Anticancer Res. 2017;37:4629-4634.
     PubMed     Abstract available
     
     
     
163. HUO X, Xiao X, Zhang S, Zhou D, et al
     Association of Intron Microsatellite Instability and Exon Mutational Profile of TP53 in Human Gastric Cancers.
     Anticancer Res. 2017;37:4507-4514.
     PubMed     Abstract available
     
     
     
164. YIN J, Cui Y, Li L, Ji J, et al
     Overexpression of EPHB4 Is Associated with Poor Survival of Patients with Gastric Cancer.
     Anticancer Res. 2017;37:4489-4497.
     PubMed     Abstract available
     
     
     
165. LI L, Cui Y, Ji JF, Jiang WG, et al
     Clinical Correlation Between WISP2 and beta-Catenin in Gastric Cancer.
     Anticancer Res. 2017;37:4469-4473.
     PubMed     Abstract available
     
     
     
166. JIANG A, Zhao H, Liu X, Yu M, et al
     Comparison of Different Muscle-Relaxant Anesthetics on Growth, Migration and Invasion of Gastric Cancer Cells.
     Anticancer Res. 2017;37:4371-4378.
     PubMed     Abstract available
     
     
     
167. MIMATSU K, Fukino N, Ogasawara Y, Saino Y, et al
     Utility of Inflammatory Marker- and Nutritional Status-based Prognostic Factors for Predicting the Prognosis of Stage IV Gastric Cancer Patients Undergoing Non-curative Surgery.
     Anticancer Res. 2017;37:4215-4222.
     PubMed     Abstract available
     
     
     
168. VIRGILIO E, Giarnieri E, Giovagnoli MR, Montagnini M, et al
     Early Gastric Cancer Exfoliating into Gastric Lavage (GL1 EGC) Shows a More Aggressive Behavior and Poorer Survival Compared to the Non-Exfoliative Counterpart (GL0 EGC).
     Anticancer Res. 2017;37:4199-4203.
     PubMed     Abstract available
     
     
     
169. LIU L, Zhao H, Sheng L, Yang P, et al
     Collision of Lymphoepithelioma-like Carcinoma with Diffuse Large B-cell Lymphoma of the Stomach: A Case Report.
     Anticancer Res. 2017;37:4569-4573.
     PubMed     Abstract available
     
     
     
170. GONG Z, Mu Y, Chen J, Chu H, et al
     Expression and Significance of Cyclophilin J in Primary Gastric Adenocarcinoma.
     Anticancer Res. 2017;37:4475-4481.
     PubMed     Abstract available
     
     
     July 2017
171. TAKIMOTO R, Kamigaki T, Okada S, Matsuda E, et al
     Efficacy of Adoptive Immune-cell Therapy in Patients with Advanced Gastric Cancer: A Retrospective Study.
     Anticancer Res. 2017;37:3947-3954.
     PubMed     Abstract available
     
     
     
172. SATAKE H, Kondo M, Mizumoto M, Kotake T, et al
     Phase I Study of Neoadjuvant Chemotherapy with Capecitabine and Oxaliplatin for Locally Advanced Gastric Cancer.
     Anticancer Res. 2017;37:3703-3710.
     PubMed     Abstract available
     
     
     
173. KAITO A, Kinoshita T, Tokunaga M, Sunagawa H, et al
     Prognostic Factors and Recurrence Pattern of Far-advanced Gastric Cancer with Pathologically-positive Para-aortic Lymph Nodes.
     Anticancer Res. 2017;37:3685-3692.
     PubMed     Abstract available
     
     
     
174. KASHIHARA H, Shimada M, Yoshikawa K, Higashijima J, et al
     Correlation Between Thrombospondin-1 Expression in Non-cancer Tissue and Gastric Carcinogenesis.
     Anticancer Res. 2017;37:3547-3552.
     PubMed     Abstract available
     
     
     June 2017
175. MOON JH, Fujiwara Y, Hirao M, Imamura H, et al
     Randomized Controlled Trial of Adjuvant Chemotherapy with Fluoropyrimidines Versus Surgery-alone for Gastric Cancer.
     Anticancer Res. 2017;37:3061-3067.
     PubMed     Abstract available
     
     
     
176. TOKUMOTO M, Tanaka H, Tauchi Y, Tamura T, et al
     Immunoregulatory Function of Lymphatic Endothelial Cells in Tumor-draining Lymph Nodes of Human Gastric Cancer.
     Anticancer Res. 2017;37:2875-2883.
     PubMed     Abstract available
     
     
     
177. VIRGILIO E, Proietti A, D'Urso R, Cardelli P, et al
     Measuring Intragastric Tumor Markers in Gastric Cancer Patients: a Systematic Literature Review on Significance and Reliability.
     Anticancer Res. 2017;37:2817-2821.
     PubMed     Abstract available
     
     
     
178. ARATANI K, Komatsu S, Ichikawa D, Ohashi T, et al
     Overexpression of EGFR as an Independent Prognostic Factor in Adenocarcinoma of the Esophagogastric Junction.
     Anticancer Res. 2017;37:3129-3135.
     PubMed     Abstract available
     
     
     May 2017
179. KANAZAWA Y, Fujita I, Kakinuma D, Arai H, et al
     Initial Experience with Nab-Paclitaxel for Patients with Advanced Gastric Cancer: Safety and Efficacy.
     Anticancer Res. 2017;37:2715-2720.
     PubMed     Abstract available
     
     
     
180. INADOMI K, Kusaba H, Matsushita Y, Tanaka R, et al
     Efficacy and Safety Analysis of Oxaliplatin-based Chemotherapy for Advanced Gastric Cancer.
     Anticancer Res. 2017;37:2663-2671.
     PubMed     Abstract available
     
     
     
181. DA SILVA OLIVEIRA KC, Bona AB, DA Silva FJ, Pinheiro TM, et al
     Expression of hsa-miR-9 and MYC Copy Number Variation in Hereditary Diffuse Gastric Cancer.
     Anticancer Res. 2017;37:2401-2406.
     PubMed     Abstract available
     
     
     April 2017
182. TAHARA T, Tahara S, Horiguchi N, Kawamura T, et al
     Telomere Length in Leukocyte DNA in Gastric Cancer Patients and its Association with Clinicopathological Features and Prognosis.
     Anticancer Res. 2017;37:1997-2001.
     PubMed     Abstract available
     
     
     
183. KUNIZAKI M, Fukuda A, Wakata K, Tominaga T, et al
     Clinical Significance of Serum p53 Antibody in the Early Detection and Poor Prognosis of Gastric Cancer.
     Anticancer Res. 2017;37:1979-1984.
     PubMed     Abstract available
     
     
     March 2017
184. FUKUCHI M, Mochiki E, Ishiguro T, Ogura T, et al
     Efficacy of Conversion Surgery Following S-1 plus Cisplatin or Oxaliplatin Chemotherapy for Unresectable Gastric Cancer.
     Anticancer Res. 2017;37:1343-1347.
     PubMed     Abstract available
     
     
     
185. MITA K, Ito H, Ota E, Takahashi K, et al
     Adjuvant Chemotherapy with S-1 plus Cisplatin for Patients with Stage III Gastric Cancer After Curative Resection.
     Anticancer Res. 2017;37:1329-1333.
     PubMed     Abstract available
     
     
     
186. AHN SY, Kim J, Kim MA, Choi J, et al
     Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer.
     Anticancer Res. 2017;37:1127-1138.
     PubMed     Abstract available
     
     
     
187. DAI X, Liu D, Liu M, Zhang X, et al
     Anti-metastatic Efficacy of Traditional Chinese Medicine (TCM) Ginsenoside Conjugated to a VEFGR-3 Antibody on Human Gastric Cancer in an Orthotopic Mouse Model.
     Anticancer Res. 2017;37:979-986.
     PubMed     Abstract available
     
     
     February 2017
188. SATOH T, Kaira K, Takahashi K, Takahashi N, et al
     Prognostic Significance of the Expression of CD98 (4F2hc) in Gastric Cancer.
     Anticancer Res. 2017;37:631-636.
     PubMed     Abstract available
     
     
     
189. BAUER G
     Central Signaling Elements of Intercellular Reactive Oxygen/Nitrogen Species-dependent Induction of Apoptosis in Malignant Cells.
     Anticancer Res. 2017;37:499-513.
     PubMed     Abstract available
     
     
     
190. BACKMAN S, Norlen O, Eriksson B, Skogseid B, et al
     Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing.
     Anticancer Res. 2017;37:705-712.
     PubMed     Abstract available
     
     
     
191. PROUET P, Giri S, Wiedower E, Fintel A, et al
     Addition of Rituximab to Chemotherapy Reduced the Rate of Surgery for Gastric-DLBCL Without Increasing Early Mortality.
     Anticancer Res. 2017;37:813-817.
     PubMed     Abstract available
     
     
     January 2017
192. OGATA K, Yanai M, Kuriyama K, Suzuki M, et al
     Double Endoscopic Intraluminal Operation (DEILO) for Early Gastric Cancer: Outcome of Novel Procedure for Endoscopic Submucosal Dissection.
     Anticancer Res. 2017;37:343-347.
     PubMed     Abstract available
     
     
     
193. SUGIYAMA K, Narita Y, Kadowaki S, Ura T, et al
     Platinum-based Doublet Chemotherapy for Advanced Gastric Cancer with Disseminated Intravascular Coagulation.
     Anticancer Res. 2017;37:309-313.
     PubMed     Abstract available
     
     
     
194. JUKIC Z, Radulovic P, Stojkovic R, Mijic A, et al
     Gender Difference in Distribution of Estrogen and Androgen Receptors in Intestinal-type Gastric Cancer.
     Anticancer Res. 2017;37:197-202.
     PubMed     Abstract available
     
     
     
195. KOGURE N, Yokobori T, Ogata K, Altan B, et al
     Low Expression of FBXO45 Is Associated with Gastric Cancer Progression and Poor Prognosis.
     Anticancer Res. 2017;37:191-196.
     PubMed     Abstract available
     
     
     
196. LEE D, Yu EJ, Ham IH, Hur H, et al
     Clinicopathological Implication of Insulin-like Growth Factor-II mRNA-Binding Protein 3 (IMP3) Expression in Gastric Cancer.
     Anticancer Res. 2017;37:135-142.
     PubMed     Abstract available
     
     
     December 2016
197. FUKUCHI M, Mochiki E, Ishiguro T, Ogura T, et al
     Efficacy of Nab-Paclitaxel as Second-line Chemotherapy for Unresectable or Recurrent Gastric Cancer.
     Anticancer Res. 2016;36:6699-6703.
     PubMed     Abstract available
     
     
     
198. TOIYAMA Y, Shimura T, Yasuda H, Fujikawa H, et al
     Clinical Burden of C-Reactive Protein/Albumin Ratio Before Curative Surgery for Patients with Gastric Cancer.
     Anticancer Res. 2016;36:6491-6498.
     PubMed     Abstract available
     
     
     November 2016
199. ZHENG LC, Yang MD, Kuo CL, Lin CH, et al
     Norcantharidin-induced Apoptosis of AGS Human Gastric Cancer Cells Through Reactive Oxygen Species Production, and Caspase- and Mitochondria-dependent Signaling Pathways.
     Anticancer Res. 2016;36:6031-6042.
     PubMed     Abstract available
     
     
     
200. HAYASHI N, Kataoka H, Yano S, Kikuchi JI, et al
     Anticancer Effects of a New Aminosugar-conjugated Platinum Complex Agent Against Cisplatin-resistant Gastric Cancer.
     Anticancer Res. 2016;36:6005-6009.
     PubMed     Abstract available
     
     
     October 2016
201. ARIGAMI T, Uenosono Y, Ishigami S, Yanagita S, et al
     Clinical Impact of Stomach-partitioning Gastrojejunostomy with Braun Enteroenterostomy for Patients with Gastric Outlet Obstruction Caused by Unresectable Gastric Cancer.
     Anticancer Res. 2016;36:5431-5436.
     PubMed     Abstract available
     
     
     
202. ALTAN B, Yokobori T, Ide M, Bai T, et al
     High Expression of MRE11-RAD50-NBS1 Is Associated with Poor Prognosis and Chemoresistance in Gastric Cancer.
     Anticancer Res. 2016;36:5237-5247.
     PubMed     Abstract available
     
     
     
203. YAWATA K, Osada S, Tanahashi T, Matsui S, et al
     The Significant Role of Cyclin D1 in the Synergistic Growth-inhibitory Effect of Combined Therapy of Vandetanib with 5-Fluorouracil for Gastric Cancer.
     Anticancer Res. 2016;36:5215-5226.
     PubMed     Abstract available
     
     
     
204. LEMOINE N, Adenis A, Bouche O, Duhamel A, et al
     Signet Ring Cells and Efficacy of First-line Chemotherapy in Advanced Gastric or Oesogastric Junction Adenocarcinoma.
     Anticancer Res. 2016;36:5543-5549.
     PubMed     Abstract available
     
     
     
205. KNIEF J, Reddemann K, Petrova E, Herhahn T, et al
     High Density of Tumor-infiltrating B-Lymphocytes and Plasma Cells Signifies Prolonged Overall Survival in Adenocarcinoma of the Esophagogastric Junction.
     Anticancer Res. 2016;36:5339-5345.
     PubMed     Abstract available
     
     
     September 2016
206. KIM EY, Jun KH, Jung JH, Jo YS, et al
     Laparoscopic Gastrectomy Followed by Chemotherapy for Advanced Gastric Cancer Diagnosed During Pregnancy: A Case Report.
     Anticancer Res. 2016;36:4813-6.
     PubMed     Abstract available
     
     
     
207. KIM DJ, Kim W
     Laparoscopy-assisted Proximal Gastrectomy with Double Tract Anastomosis Is Beneficial for Vitamin B12 and Iron Absorption.
     Anticancer Res. 2016;36:4753-8.
     PubMed     Abstract available
     
     
     August 2016
208. ROMAN LD, Lukyanchuk R, Sablin OA, Araslanova EI, et al
     Prevalence of H. pylori Infection and Atrophic Gastritis in a Population-based Screening with Serum Biomarker Panel (GastroPanel(R)) in St. Petersburg.
     Anticancer Res. 2016;36:4129-38.
     PubMed     Abstract available
     
     
     June 2016
209. KOMATSU S, Ichikawa D, Kosuga T, Okamoto K, et al
     Clinical Impact of Laparoscopy and Endoscopy Cooperative Surgery (LECS) on Gastric Submucosal Tumor After its Standardization.
     Anticancer Res. 2016;36:3041-7.
     PubMed     Abstract available
     
     
     
210. YONENAGA Y, Kurosawa M, Mise M, Yamagishi M, et al
     Pancreatic-type Acinar Cell Carcinoma of the Stomach Included in Multiple Primary Carcinomas.
     Anticancer Res. 2016;36:2855-64.
     PubMed     Abstract available
     
     
     March 2016
211. ZIMMERMANN N, Lazar-Karsten P, Keck T, Billmann F, et al
     Expression Pattern of CDX2, Estrogen and Progesterone Receptors in Primary Gastroenteropancreatic Neuroendocrine Tumors and Metastases.
     Anticancer Res. 2016;36:921-4.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Gastric Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: